 |
|
|
| |
The Impact of Hepatitis C Diagnosis on Substance-Use Behaviors in Patients Engaged in Opioid Substitution Therapy - HCV screening/diagnosis reduces drug use by 33% (non-prescribed opioids, benzodiazepines and cocaine)
|
| |
| |
Reported by Jules Levin
AASLD Annual Meeting, October 22nd 2017; Washington DC, US
Hooman Farhang Zangneh, Joseph K. Eibl, Graham Gauthier, David Pellegrini, Jordan J Feld, David C Marsh, Hemant Shah
"Hepatitis C - with an estimated prevalence of 0.3 to 0.9 percent among all Canadians - is more common among people who are opioid dependent (prevalence approaching 65-67%)......study reports: 33% Reduced Substance Abuse 1 Year After Being Tested & Diagnosed for HCV....reduce their use of non-prescribed opioids, benzodiazepines and cocaine than those who tested negative for the virus......They also noted, through urine toxicology, those who tested positive for HCV reduced their consumption of non-prescribed opioids - when compared to those who tested negative. In fact, this group had significantly lower positive urine drug screens for non-prescribed opioids, benzodiazepines and cocaine."......."Our study showed awareness of HCV infection among this particular population may motivate them to reduce their consumption and hopefully high-risk behavior," explains Dr. Zangneh. "Furthermore, bearing in mind that effective, accessible and durable curative options are currently available, it is highly advisable to screen these clients and use this opportunity as an appropriate time to share motivational and educational resources and information with them. This way, we can provide enhanced support for them, which will have beneficial effects in both individual and societal levels."
sIDWeek: Implementation of Hepatitis C Elimination - John Ward, MD, CDC (10/12/17)
33% Reduced Substance Abuse 1 Year After Being Tested & Diagnosed for HCV....reduce their use of non-prescribed opioids, benzodiazepines and cocaine than those who tested negative for the virus.
IDWeek: Implementation of Hepatitis C Elimination - John Ward, MD, CDC (10/12/17)
|
| |
|
|
|
|
|
